BioCentury | Mar 13, 2020
Product Development

March 12 Quick Takes: WuXi AppTec’s Wuhan site back online; plus SOX relief, AZ, BMS, Nicox-Ocumesion, Tyligand-Context

All WuXi AppTec Chinese sites operating  WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) said it has resumed operations at its Wuhan facility, which provides discovery chemistry services. The company has now restarted operations at all its...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

Boehringer’s Ofev approved as first therapy for lung scarring disease  FDA approved Ofev nintedanib from Boehringer Ingelheim GmbH as the first therapy for chronic fibrosing interstitial lung diseases; the NDA had received Priority Review. The...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

Cancer play Treadwell debuted Monday as Tio Bioventures’s first portfolio company with $27 million in seed funding and a pair of differentiated oral small molecules that are already in the clinic. Founded last year, Tio...
BC Extra | Nov 22, 2019
Clinical News

Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

Tecentriq continues to carve out a niche in the crowded PD-1/PD-L1 space as new survival data for the drug in the combination with Avastin in hepatocellular carcinoma pave the way for the regimen to become...
BC Extra | Oct 21, 2019
Clinical News

With Avastin on board, Tecentriq improves overall survival in HCC

Roche’s Tecentriq is the first checkpoint inhibitor to show a statistically significant survival benefit in the hard-to-treat indication of hepatocellular carcinoma. Unlike the other compounds, the anti-PD-L1 mAb was combined with a VEGF inhibitor to...
BC Extra | Aug 2, 2019
Clinical News

SillaJen, Transgene fall with latest oncolytic virus setback

The failure of Pexa-Vec from Transgene and SillaJen in a Phase III study is the latest blow to the oncolytic virus field, but it may say less about the modality as a whole than about...
BC Extra | Jun 25, 2019
Company News

Otezla divestiture makes next launches mission critical for BMS

The molecule that started Celgene's market decline, leading to its eventual takeout, is now being off-loaded to allow BMS to close the deal. Losing it from the line-up will raise the pressure for successful launches...
BC Extra | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
BC Extra | Jun 3, 2019
Clinical News

Keytruda unlikely to face pushback from clinicians in HCC

Despite a Phase III miss for Merck & Co.'s Keytruda pembrolizumab to treat hepatocellular carcinoma, enthusiasm for the PD-1 inhibitor in the indication remains, according to comments made Sunday at the American Society of Clinical...
Items per page:
1 - 10 of 764